Vericel (VCEL) Expected to Announce Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $63.6770 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.45. The company had revenue of $92.92 million for the quarter, compared to the consensus estimate of $92.66 million. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The firm’s revenue was up 23.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.38 EPS. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Performance

Shares of NASDAQ:VCEL traded up $0.96 during midday trading on Wednesday, reaching $37.77. The company’s stock had a trading volume of 90,587 shares, compared to its average volume of 574,073. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 121.84 and a beta of 1.15. The firm has a 50 day moving average price of $34.02 and a two-hundred day moving average price of $36.19. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $45.97.

Insiders Place Their Bets

In related news, insider Jonathan Mark Hopper sold 3,472 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $121,520.00. Following the transaction, the insider directly owned 75,556 shares of the company’s stock, valued at approximately $2,644,460. This represents a 4.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new position in Vericel during the fourth quarter worth $27,000. Quarry LP acquired a new position in Vericel during the fourth quarter worth $31,000. Truvestments Capital LLC raised its holdings in Vericel by 175.4% during the fourth quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock worth $55,000 after buying an additional 977 shares during the last quarter. Empowered Funds LLC acquired a new position in Vericel during the fourth quarter worth $58,000. Finally, Osaic Holdings Inc. raised its holdings in shares of Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 353 shares during the last quarter.

Analysts Set New Price Targets

VCEL has been the topic of a number of recent analyst reports. Leerink Partners reissued an “outperform” rating and issued a $46.00 price objective on shares of Vericel in a research note on Tuesday, March 10th. Truist Financial dropped their target price on shares of Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Finally, HC Wainwright boosted their target price on shares of Vericel from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.40.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.